Efficacy and safety of less frequent dosing with elranatamab (ELRA) in patients with relapsed or refractory multiple myeloma (RRMM): A US subgroup analysis from MagnetisMM-3. Positron emission ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results